As the annual meeting for the American Society of Clinical Oncology (ASCO) is underway, we are starting to see some winners shake out from it. Currently one of the biggest winners is Vascular Biogenics…
Ocular Therapeutix shares plunged early on Monday following less-than-favorable results, although the news was not all bad.
Many speculative calls are made on the biotech stocks. It is here that fortunes can easily be made. The dark side is that these speculative companies quite frequently fail to live up to their…
A few biotech companies made fantastic runs in Thursday’s session. We have included information about each company, as well as recent trading activity and the consensus price target.
A new study from IMS Health has projected that the global market for cancer treatments rose to $107 billion in 2015.
Nant Health entered the market with a bang on Thursday. Despite pricing at $14 per share, the stock opened at $16.11 and went higher.
Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology (ASCO) annual meeting, and it has issued a report on what it is looking…
Clearside Biomedical expects to price more than 7 million shares at $7 per share for an initial public offering valued up to nearly $58 million.
StemCells just reminded investors and speculators alike just how dangerous it can be to invest in biotech and biohealth companies.
AC Immune has filed with the U.S. Securities & Exchange Commission (SEC) to pursue an initial public offering (IPO).
Jazz Pharmaceuticals announced Tuesday morning that it has reached a definitive agreement to acquire Celator Pharmaceuticals for about $1.5 billion.
Medical device maker Medtronic reported fourth-quarter and fiscal-year 2016 results before U.S. markets opened Tuesday morning.
Mississippi has the most obese residents of any of the 50 states. As a by-product, cases of diabetes and the costs of health care are high, along with premature deaths.
The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.
Here are seven speculative biotech and biohealth players in which analyst calls during the week ending May 27 have given major upside projections.
